Zhang J N, Liu X G, Zhu M, Chiu F C, Li R C
Department of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories.
J Chemother. 1998 Oct;10(5):354-9. doi: 10.1179/joc.1998.10.5.354.
This study was carried out to elucidate the possible mechanism(s) responsible for reduced oral rifampicin bioavailability after multiple dosing. In addition to autoinduction, the relative contribution of the two possible controlling factors, e.g., intestinal metabolism and microbial degradation, was investigated using a rat model. Pharmacokinetic studies were carried out to assess the absolute rifampicin bioavailability by both oral and intravenous drug administration before and after 8 daily doses of 25 mg/kg. To estimate the possible involvement of microbial degradation, rifampicin kinetics were also assessed in rats on day 8 after receiving multiple oral dosing and concurrent administration of nonabsorbable triple antibiotics for gut sterilization 3 days prior to the study day. Pharmacokinetic parameters were generated by noncompartmental analysis. The results revealed a significant decrease in rifampicin levels for rats after multiple exposure, compared to single dosing; the mean clearance determined by intravenous dosing increased by 43% from 3.7 ml/min/kg and the half-life decreased by 24% from 238 min. However, the extent of decrease in rifampicin exposure following multiple dosing was substantially greater for rats dosed orally than intravenously; estimated absolute oral bioavailability decreased by 15% from 0.89 on day 1 to 0.76 on day 8. No apparent alterations in any of the pharmacokinetic parameters were observed after gut sterilization, suggesting minimal contribution of microbial degradation to the reduction in oral rifampicin absorption after multiple dosing. In addition to hepatic enzyme autoinduction, these results strongly suggest the involvement of enhanced intestinal metabolism as a contributing factor to the decrease in oral rifampicin bioavailability following prolonged exposure.
本研究旨在阐明多次给药后口服利福平生物利用度降低的可能机制。除自身诱导作用外,还使用大鼠模型研究了两个可能的控制因素,即肠道代谢和微生物降解的相对贡献。进行了药代动力学研究,以评估在每日8次给予25 mg/kg剂量前后,口服和静脉给药时利福平的绝对生物利用度。为了评估微生物降解的可能作用,在研究当天前3天接受多次口服给药并同时给予不可吸收的三联抗生素进行肠道灭菌的大鼠中,于第8天也评估了利福平的动力学。通过非房室分析得出药代动力学参数。结果显示,与单次给药相比,多次暴露后大鼠体内利福平水平显著降低;静脉给药测定的平均清除率从3.7 ml/min/kg增加了43%,半衰期从238分钟减少了24%。然而,多次给药后口服给药的大鼠利福平暴露量的降低程度明显大于静脉给药;估计的绝对口服生物利用度从第1天的0.89降至第8天的0.76,降低了15%。肠道灭菌后未观察到任何药代动力学参数有明显变化,这表明微生物降解对多次给药后口服利福平吸收减少的贡献最小。除肝酶自身诱导作用外,这些结果强烈表明,肠道代谢增强是长期暴露后口服利福平生物利用度降低的一个促成因素。